Major achievements
The year 2021 has been another difficult one due to COVID-19. Despite the complexity of the situation, I am always so grateful for your continuous support and for the hard work of the ALWP team and contributors. However, I am blessed by the profound appreciation we received for the extraordinary research efforts of the last 12 months.

As you probably know, the number of HSCT procedures for patients with acute leukemia continues to grow. This increase is accompanied by improving results, due to both lower risk of relapse (maintenance therapy post HSCT, but also better disease control prior to HSCT), and decreased non-relapse mortality. In 2021, as in previous years, the ALWP have published an amazing number of high-level peer reviewed papers in reputable high-impact factor journals. Our key initiative of aiming to collect next-generation sequencing (NGS) data and use of novel drugs is moving well in the right direction with several thousands of cases being documented and collected. This initiative is crucial if we want to embrace the latest advances in the field, especially the role of NGS as a backbone of the clinical decision-making process, both at diagnosis and at time of relapse. NGS not only allows assessment of the unique clonal hierarchy of an individual patient, but also identification of «druggable» mutations.

I am very grateful for your tireless efforts in sending such complex data, which will definitely lead to the generation of new knowledge to further advance the management of acute leukemia.

**Principal research studies**

[Trends in allogeneic stem cell transplantation (HSCT) over two decades in patients with secondary acute myelogenous leukemia (sAML) being transplanted from sibling (MSD) or unrelated donors (UD). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.](#)

**Group**

Acute Leukemia Working Party (ALWP)

**Principal investigator**

Arnon Nagler

[Trends in donor characteristics for unrelated Stem Cell Transplantation in patients with acute myeloid leukemia](#)

**Group**
Acute Leukemia Working Party (ALWP)
Principal investigator
Arnon Nagler
Trends in non sibling donor in HSCT CR2

Group
Acute Leukemia Working Party (ALWP)
Principal investigator
Mohamad Mohty
Haploidentical versus matched sibling donors hematopoietic stem cell transplantation for adult patients with relapsed/refractory acute lymphoblastic leukemia

Group
Acute Leukemia Working Party (ALWP)
Principal investigator
Arnon Nagler
Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT

Group
Acute Leukemia Working Party (ALWP)
Principal investigator
Annalisa Ruggeri
PTCY MMUD vs Haplo in active disease for AML

Group
Acute Leukemia Working Party (ALWP)
Principal investigator
Frédéric Baron
Outcome of patients with Intermediate risk Acute Myelogenous Leukemia in first remission and no detectable residual disease (MRD negative) transplanted with a haploidentical donor versus autografted

Group
Acute Leukemia Working Party (ALWP)
Type of transplant

- Principal investigator
Norbert-Claude GORIN
The role of measurable residual disease (MRD) at the time of allogeneic stem cell transplantation in patients with AML in CR transplanted from unrelated donors with Post transplant cyclophosphamide
Group
Acute Leukemia Working Party (ALWP)
Principal investigator
Arnon Nagler
COLLECTION OF NEXT-GENERATION SEQUENCING (NGS) DATA AND USE OF NOVEL DRUGS IN ACUTE LEUKEMIA PATIENTS
Group
Acute Leukemia Working Party (ALWP)
Type of transplant
-
Principal investigator
Prof M. Mohty

Key publications

2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Jordi Esteve
Journal
Leukemia.
2021
Second allogeneic haemopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Mohamed A Kharfan-Dabaja
Journal
Br J Haematol.
2021
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Acute Leukemia Working Party (ALWP)
1st listed author
Maria H Gilleece

Journal
Blood Cancer J.
2021
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

Acute Leukemia Working Party (ALWP)
1st listed author
Annalisa Paviglianiti

Journal
Bone Marrow Transplant.
2021
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Acute Leukemia Working Party (ALWP)
1st listed author
Giorgia Battipaglia

Journal
Cancer.
See the full list of the ALWP 2021 publications
<table>
<thead>
<tr>
<th>Year</th>
<th>Oral Presentations</th>
<th>Poster Presentations</th>
<th>Educational Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>24</td>
<td>17</td>
<td>1</td>
</tr>
<tr>
<td>2020</td>
<td>17</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>2021</td>
<td>10</td>
<td>8</td>
<td>1</td>
</tr>
</tbody>
</table>